0001628280-23-029148.txt : 20230811
0001628280-23-029148.hdr.sgml : 20230811
20230811192620
ACCESSION NUMBER: 0001628280-23-029148
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230809
FILED AS OF DATE: 20230811
DATE AS OF CHANGE: 20230811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stewart Murray
CENTRAL INDEX KEY: 0001723450
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 231165760
MAIL ADDRESS:
STREET 1: C/O NOVELION THERAPEUTICS INC.
STREET 2: 1800-510 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6B OM3
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wk-form4_1691796370.xml
FORM 4
X0508
4
2023-08-09
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001723450
Stewart Murray
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
MA
02134
1
1
0
0
Interim Chief Medical Officer
0
Common Stock
2023-08-09
4
A
0
269893
0
A
276560
D
Common Stock
2023-08-10
4
S
0
130056
1.06
D
146504
D
Represents shares of common stock acquired upon acceleration of the vesting of a performance-based restricted stock unit grant.
Represents nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Adam S. Mostafa, attorney-in-fact
2023-08-11